{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:38:19Z","timestamp":1776296299022,"version":"3.50.1"},"reference-count":46,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ketamine and esketamine (ESK) offer new treatment options for resistant\n                        depression. Unlike traditional antidepressants, they can be used in\n                        combination with non-selective monoamine oxidase inhibitors (NS-MAOI)\n                        without the risk of serotonergic syndrome. However, potential\n                        sympathomimetic synergy may lead to elevated blood pressure (BP). This\n                        series investigates whether cardiovascular parameters (heart rate, systolic\n                        [SP], and diastolic [DP] pressures) increase during ESK sessions and whether\n                        the ESK+NS-MAOI combination is associated with BP elevations.<\/jats:p>\n                  <jats:p>We collected cardiovascular parameters for ESK sessions conducted between\n                        2018 and 2022. These parameters were measured at baseline and every 30\u2009min\n                        for 2\u2009h. Patients were categorized into two non-equivalent groups: those\n                        receiving ESK alone and those receiving ESK+NS-MAOI. A Bayesian random model\n                        was used to estimate the evolution of these parameters, while a Bayesian\n                        hierarchical model assessed factors contributing to BP elevation.<\/jats:p>\n                  <jats:p>ESK sessions (n=193), of which 116 involved NS-MAOI, were performed in 13\n                        patients. SP, DP, and heart rate showed peak increases during sessions, but\n                        these changes were not clinically significant (SP+8.68\u2009mmHg, DP+6.57\u2009mmHg,\n                        and heart rate+3.5 bpm). No significant differences were found between the\n                        ESK-alone and ESK+NS-MAOI groups. The combination was not identified as a\n                        factor linked to BP elevations.<\/jats:p>\n                  <jats:p>These findings align with previous research on ketamine derivatives and\n                        suggest minimal peripheric sympathomimetic synergy with NS-MAOI. Bayesian\n                        models were used to account for biases intrinsically related to these\n                        ecological data and provide a foundation for future open adversarial\n                        collaborations. Registration NCT05530668<\/jats:p>","DOI":"10.1055\/a-2590-3469","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:24:32Z","timestamp":1748892272000},"page":"273-283","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors\n                    and Intranasal Esketamine Combination in Depression \u2013 A Quasi-Experimental\n                    Design with Bayesian Analyses"],"prefix":"10.1055","volume":"58","author":[{"given":"Ludovic C.","family":"Dormegny-Jeanjean","sequence":"additional","affiliation":[{"name":"Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), department\n                    of Psychiatry of Elderly and NeuroStimulation (PPANS), University Hospital of\n                    Strasbourg, Strasbourg, France"},{"name":"Physiology and Functional Explorations Department, University Hospital\n                    of Strasbourg, Strasbourg, France"},{"name":"CNRS UMR 7357 ICube, FMTS, University of Strasbourg, Strasbourg,\n                    France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzie","family":"Lenoir","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospital of Strasbourg, Strasbourg,\n                    France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilia","family":"Humbert","sequence":"additional","affiliation":[{"name":"Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), department\n                    of Psychiatry of Elderly and NeuroStimulation (PPANS), University Hospital of\n                    Strasbourg, Strasbourg, France"},{"name":"CNRS UMR 7357 ICube, FMTS, University of Strasbourg, Strasbourg,\n                    France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier A. E.","family":"Mainberger","sequence":"additional","affiliation":[{"name":"Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), department\n                    of Psychiatry of Elderly and NeuroStimulation (PPANS), University Hospital of\n                    Strasbourg, Strasbourg, France"},{"name":"CNRS UMR 7357 ICube, FMTS, University of Strasbourg, Strasbourg,\n                    France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coraline","family":"Lozere","sequence":"additional","affiliation":[{"name":"Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), department\n                    of Psychiatry of Elderly and NeuroStimulation (PPANS), University Hospital of\n                    Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Meyer","sequence":"additional","affiliation":[{"name":"Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), department\n                    of Psychiatry of Elderly and NeuroStimulation (PPANS), University Hospital of\n                    Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Geny","sequence":"additional","affiliation":[{"name":"Physiology and Functional Explorations Department, University Hospital\n                    of Strasbourg, Strasbourg, France"},{"name":"EA 3072, \u201cMitochondria, Oxidative Stress and Muscle Protection\u201d,\n                    University of Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Michel","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospital of Strasbourg, Strasbourg,\n                    France"},{"name":"UR7296 \u201cLaboratory of NeuroCardiovascular Pharmacology and Toxicology\u201d,\n                    University of Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack R.","family":"Foucher","sequence":"additional","affiliation":[{"name":"Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), department\n                    of Psychiatry of Elderly and NeuroStimulation (PPANS), University Hospital of\n                    Strasbourg, Strasbourg, France"},{"name":"CNRS UMR 7357 ICube, FMTS, University of Strasbourg, Strasbourg,\n                    France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"de Crespin de Billy","sequence":"additional","affiliation":[{"name":"Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), department\n                    of Psychiatry of Elderly and NeuroStimulation (PPANS), University Hospital of\n                    Strasbourg, Strasbourg, France"},{"name":"CNRS UMR 7357 ICube, FMTS, University of Strasbourg, Strasbourg,\n                    France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant\n                    depression: An international expert opinion on the available evidence and\n                    implementation","volume":"178","author":"R S McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.13r01515","article-title":"Reducing the burden of difficult-to-treat major depressive disorder: Revisiting\n                    monoamine oxidase inhibitor therapy","volume":"15","author":"L Culpepper","year":"2013","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2147\/NDT.S59107","article-title":"EMSAM (deprenyl patch): How a promising antidepressant was underutilized","volume":"10","author":"G M Asnis","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852922000906","article-title":"The prescriber\u2019s guide to classic MAO inhibitors (phenelzine, tranylcypromine,\n                    isocarboxazid) for treatment-resistant depression","author":"V Van den Eynde","year":"2022","journal-title":"CNS Spectr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.biopsych.2005.11.016","article-title":"A review of serotonin toxicity data: Implications for the mechanisms of\n                    antidepressant drug action","volume":"59","author":"P K Gillman","year":"2006","journal-title":"Biol Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00702-018-1932-y","article-title":"A reassessment of the safety profile of monoamine oxidase inhibitors:\n                    Elucidating tired old tyramine myths","volume":"125","author":"P K Gillman","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"110603","DOI":"10.1016\/j.pnpbp.2022.110603","article-title":"Adjunctive dopaminergic enhancement of esketamine in treatment-resistant\n                    depression","volume":"119","author":"J Cook","year":"2022","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biosystems.2015.05.001","article-title":"A model of dopamine modulated glutamatergic synapse","volume":"136","author":"V Di Maio","year":"2015","journal-title":"Biosystems"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e1012688","DOI":"10.1371\/journal.pcbi.1012688","article-title":"Dopamine facilitates the response to glutamatergic inputs in astrocyte cell\n                    models","volume":"20","author":"T O Bezerra","year":"2024","journal-title":"PLoS Comput Biol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: Meta-analysis and review of\n                    the implications for neuropsychiatric disorders","volume":"23","author":"M Kokkinou","year":"2018","journal-title":"Mol Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D2\/3 receptor binding in the striatum after a single\n                    administration of esketamine, but not R-ketamine: A PET study in conscious\n                    monkeys","volume":"267","author":"K Hashimoto","year":"2017","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euroneuro.2017.05.007","article-title":"Tranylcypromine in mind (Part I): Review of pharmacology","volume":"27","author":"S Ulrich","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/s0006-3223(00)00976-8","article-title":"Modulation of amphetamine-induced striatal dopamine release by ketamine in\n                    humans: Implications for schizophrenia","volume":"48","author":"L S Kegeles","year":"2000","journal-title":"Biol Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s00101-008-1331-0","article-title":"Sympathomimetic effects of low-dose S(+)-ketamine. Effect of propofol\n                    dosage","volume":"57","author":"C Timm","year":"2008","journal-title":"Anaesthesist"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/00000542-198603000-00010","article-title":"Differential effects of ketamine isomers on neuronal and extraneuronal\n                    catecholamine uptake mechanisms","volume":"64","author":"P M Lundy","year":"1986","journal-title":"Anesthesiology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jad.2020.01.002","article-title":"Adjunctive intranasal esketamine for major depressive disorder: A systematic\n                    review of randomized double-blind controlled-placebo studies","volume":"265","author":"W Zheng","year":"2020","journal-title":"J Affect Disord"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14656566.2019.1683161","article-title":"Efficacy and safety of intranasal esketamine for the treatment of major\n                    depressive disorder","volume":"21","author":"J Kryst","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1016\/s0952-8180(97)00119-0","article-title":"Adverse drug interactions in anesthesia","volume":"9","author":"J G Bovill","year":"1997","journal-title":"J Clin Anesth"},{"key":"ref20","first-page":"471p","article-title":"Potentiation of the cardiovascular effects of some catecholamines by a monoamine\n                    oxidase inhibitor","volume":"43","author":"M F Cuthbert","year":"1971","journal-title":"BrJ Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000158702","article-title":"Mechanism of action of indirectly acting sympathomimetic amines","volume":"24","author":"U Trendelenburg","year":"1987","journal-title":"Blood Vessels"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40263-021-00837-6","article-title":"Cardiovascular effects of combining subcutaneous or intravenous esketamine and\n                    the MAO inhibitor tranylcypromine for the treatment of depression: A\n                    retrospective cohort study","volume":"35","author":"V M Ludwig","year":"2021","journal-title":"CNS Drugs"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.4088\/JCP.11m07607","article-title":"Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of\n                    intraoperative hemodynamic events: A retrospective observational cohort\n                    study","volume":"73","author":"I M van Haelst","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.euroneuro.2015.07.021","article-title":"Combination of intravenous S-ketamine and oral tranylcypromine in\n                    treatment-resistant depression: A report of two cases","volume":"25","author":"L Bartova","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.genhosppsych.2018.05.007","article-title":"Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of\n                    depression: A letter to the editor","volume":"54","author":"R B Katz","year":"2018","journal-title":"Gen Hosp Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/jcp.0000000000001244","article-title":"The concurrent treatment with intravenous ketamine and an irreversible monoamine\n                    oxidase inhibitor for treatment-resistant depression without hypertensive\n                    crises","volume":"40","author":"JC C Wang","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.npbr.2020.02.008","article-title":"Safety and efficacy of esketamine nasal spray in a depressed patient who was\n                    being treated with tranylcypromine: A case report","volume":"36","author":"D L Dunner","year":"2020","journal-title":"Neurol Psychiat Br Research"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00131746-200407000-00005","article-title":"The role of monoamine oxidase inhibitors in current psychiatric practice","volume":"10","author":"J G Fiedorowicz","year":"2004","journal-title":"J Psychiatr Pract"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection,\n                    Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"A V Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"K Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"S A Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12874-020-00980-6","article-title":"Bayesian alternatives to null hypothesis significance testing in biomedical\n                    research: A non-technical introduction to Bayesian inference with JASP","volume":"20","author":"R Kelter","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","article-title":"Efficacy and safety of fixed doses of intranasal esketamine as an add-on therapy\n                    to oral antidepressants in Japanese patients with treatment-resistant\n                    depression: A phase 2b randomized clinical study","volume":"21","author":"N Takahashi","year":"2021","journal-title":"BMC Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a\n                    newly initiated oral antidepressant in treatment-resistant depression: A\n                    randomized double-blind active-controlled study","volume":"176","author":"V Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41569-022-00690-0","article-title":"Blood pressure and its variability: Classic and novel measurement\n                    techniques","volume":"19","author":"A E Schutte","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pnpbp.2006.08.015","article-title":"Baroreflex mechanisms in major depression","volume":"31","author":"D M Davydov","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"533872","DOI":"10.3389\/fpsyt.2020.533872","article-title":"Dopaminergic, noradrenergic, adrenal, and thyroid abnormalities in psychotic and\n                    affective disorders","volume":"11","author":"F Duval","year":"2020","journal-title":"Front Psychiatry"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.psyneuen.2018.12.017","article-title":"Vagal effects of endocrine HPA axis challenges on resting autonomic activity\n                    assessed by heart rate variability measures in healthy humans","volume":"102","author":"A Agorastos","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"ref44","first-page":"341","article-title":"Heart rate and systolic blood pressure variability: The impact of thinness and\n                    aging in human male subjects","volume":"9","author":"M Vaz","year":"2005","journal-title":"J Nutr Health Aging"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jagp.2021.09.014","article-title":"Comparison of long-term efficacy and safety of esketamine nasal spray plus oral\n                    antidepressant in younger versus older patients with treatment-resistant\n                    depression: Post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3\n                    safety and efficacy study","volume":"30","author":"R Ochs-Ross","year":"2022","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/0269881120936909","article-title":"Cardiovascular effects of repeated subanaesthetic ketamine infusion in\n                    depression","volume":"35","author":"Y-L Zhou","year":"2021","journal-title":"J Psychopharmacol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-0716-1566-9_3","article-title":"Fixed- and random-effects models","volume":"2345","author":"S Kanters","year":"2022","journal-title":"Methods Mol Biol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"A Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jad.2018.02.025","article-title":"Blood pressure safety of subanesthetic ketamine for depression: A report on 684\n                    infusions","volume":"236","author":"P Riva-Posse","year":"2018","journal-title":"J Affect Disord"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1016\/j.neuron.2023.08.027","article-title":"Accelerating scientific progress through Bayesian adversarial collaboration","volume":"111","author":"A W Corcoran","year":"2023","journal-title":"Neuron"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2217\/cer.13.73","article-title":"Bayesian data analysis in observational comparative effectiveness research:\n                    Rationale and examples","volume":"2","author":"W H Olson","year":"2013","journal-title":"J Comp Eff Res"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0269881120978398","article-title":"Repeated subcutaneous esketamine for treatment-resistant depression: Impact of\n                    the degree of treatment resistance and anxiety comorbidity","volume":"35","author":"A C Lucchese","year":"2021","journal-title":"J Psychopharmacol"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2590-3469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:35:44Z","timestamp":1762299344000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2590-3469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":46,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2590-3469","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}